Les complications peuvent-elles affecter la qualité de vie ?
Oui, elles peuvent significativement impacter la qualité de vie des patients.
Qualité de vieComplicationsTumeurs cérébrales
#5
Y a-t-il des complications à long terme ?
Des complications à long terme peuvent inclure des troubles cognitifs et des séquelles physiques.
Complications à long termeTroubles cognitifsSéquelles
Facteurs de risque
5
#1
Quels sont les principaux facteurs de risque ?
Les antécédents familiaux et certaines expositions environnementales sont des facteurs clés.
Facteurs de risqueAntécédents familiauxExpositions environnementales
#2
L'âge influence-t-il le risque de développer ces tumeurs ?
Oui, le risque augmente avec l'âge, surtout après 50 ans.
ÂgeFacteurs de risqueTumeurs cérébrales
#3
Les radiations sont-elles un facteur de risque ?
Oui, l'exposition aux radiations ionisantes est un facteur de risque connu.
RadiationsFacteurs de risqueExpositions environnementales
#4
Les maladies génétiques augmentent-elles le risque ?
Certaines maladies génétiques, comme la neurofibromatose, augmentent le risque.
Maladies génétiquesNeurofibromatoseFacteurs de risque
#5
Le sexe influence-t-il le risque de tumeurs cérébrales ?
Oui, certaines études montrent que le sexe peut influencer le risque, mais les résultats varient.
SexeFacteurs de risqueTumeurs cérébrales
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Neuro-oncological ventral antigen : Questions médicales les plus fréquentes",
"headline": "Neuro-oncological ventral antigen : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Neuro-oncological ventral antigen : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-02-04",
"dateModified": "2026-04-24",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Neuro-oncological ventral antigen"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Protéines de liaison à l'ARN",
"url": "https://questionsmedicales.fr/mesh/D016601",
"about": {
"@type": "MedicalCondition",
"name": "Protéines de liaison à l'ARN",
"code": {
"@type": "MedicalCode",
"code": "D016601",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.664.962"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Neuro-oncological ventral antigen",
"alternateName": "Neuro-Oncological Ventral Antigen",
"code": {
"@type": "MedicalCode",
"code": "D000090682",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Patrick Y Wen",
"url": "https://questionsmedicales.fr/author/Patrick%20Y%20Wen",
"affiliation": {
"@type": "Organization",
"name": "Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA."
}
},
{
"@type": "Person",
"name": "Michael Weller",
"url": "https://questionsmedicales.fr/author/Michael%20Weller",
"affiliation": {
"@type": "Organization",
"name": "Department of Neurology & Brain Tumor Center, University Hospital and University of Zürich, Zurich, Switzerland."
}
},
{
"@type": "Person",
"name": "Rimas V Lukas",
"url": "https://questionsmedicales.fr/author/Rimas%20V%20Lukas",
"affiliation": {
"@type": "Organization",
"name": "Department of Neurology (RVL), Northwestern University, Chicago, IL; The Lou & Jean Malnati Brain Tumor Institute of the Lurie Comprehensive Cancer Center (RVL), Chicago, IL; Departments of Neurology and Neurological Surgery (JWT), University of California-San Francisco; Department of Neurology (SCK), New York University, New York; Brain and Spine Tumor Center at the Perlmutter Cancer Center (SCK), New York, NY; and Department of Neurology (NAM), University of Rochester, NY."
}
},
{
"@type": "Person",
"name": "Rifaquat Rahman",
"url": "https://questionsmedicales.fr/author/Rifaquat%20Rahman",
"affiliation": {
"@type": "Organization",
"name": "Department of Radiation Oncology, Dana-Farber/Brigham and Women's Cancer Center, Boston, MA."
}
},
{
"@type": "Person",
"name": "Eudocia Q Lee",
"url": "https://questionsmedicales.fr/author/Eudocia%20Q%20Lee",
"affiliation": {
"@type": "Organization",
"name": "Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Disparities in Neuro-Oncology.",
"datePublished": "2023-10-27",
"url": "https://questionsmedicales.fr/article/37889427",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s11910-023-01314-x"
}
},
{
"@type": "ScholarlyArticle",
"name": "Expertise in surgical neuro-oncology. Results of a survey by the EANS neuro-oncology section.",
"datePublished": "2024-05-07",
"url": "https://questionsmedicales.fr/article/38831935",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.bas.2024.102822"
}
},
{
"@type": "ScholarlyArticle",
"name": "Palliative Care in Neuro-Oncology.",
"datePublished": "2024-01-04",
"url": "https://questionsmedicales.fr/article/38176423",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1055/s-0043-1777703"
}
},
{
"@type": "ScholarlyArticle",
"name": "Artificial intelligence in neuro-oncology.",
"datePublished": "2023-12-14",
"url": "https://questionsmedicales.fr/article/38161802",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/fnins.2023.1217629"
}
},
{
"@type": "ScholarlyArticle",
"name": "Cancer Predisposition Syndromes in Neuro-Oncology.",
"datePublished": "2023-12-14",
"url": "https://questionsmedicales.fr/article/38096910",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1055/s-0043-1777702"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Acides aminés, peptides et protéines",
"item": "https://questionsmedicales.fr/mesh/D000602"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines",
"item": "https://questionsmedicales.fr/mesh/D011506"
},
{
"@type": "ListItem",
"position": 4,
"name": "Nucléoprotéines",
"item": "https://questionsmedicales.fr/mesh/D009698"
},
{
"@type": "ListItem",
"position": 5,
"name": "Protéines de liaison à l'ARN",
"item": "https://questionsmedicales.fr/mesh/D016601"
},
{
"@type": "ListItem",
"position": 6,
"name": "Neuro-oncological ventral antigen",
"item": "https://questionsmedicales.fr/mesh/D000090682"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Neuro-oncological ventral antigen - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Neuro-oncological ventral antigen",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2026-05-21",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Neuro-oncological ventral antigen",
"description": "Comment détecte-t-on l'antigène ventral neuro-oncologique ?\nQuels examens sont utilisés pour le diagnostic ?\nL'antigène est-il spécifique à un type de cancer ?\nPeut-on utiliser l'antigène pour le suivi des traitements ?\nQuels marqueurs sont associés à l'antigène ventral ?",
"url": "https://questionsmedicales.fr/mesh/D000090682#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Neuro-oncological ventral antigen",
"description": "Quels symptômes sont liés aux tumeurs produisant cet antigène ?\nLes symptômes varient-ils selon le type de tumeur ?\nL'antigène provoque-t-il des symptômes spécifiques ?\nComment les symptômes évoluent-ils avec le temps ?\nLes symptômes peuvent-ils être confondus avec d'autres maladies ?",
"url": "https://questionsmedicales.fr/mesh/D000090682#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Neuro-oncological ventral antigen",
"description": "Peut-on prévenir les tumeurs associées à cet antigène ?\nQuels facteurs de risque sont connus ?\nL'alimentation joue-t-elle un rôle dans la prévention ?\nLe tabagisme est-il un facteur de risque ?\nDes examens réguliers peuvent-ils aider ?",
"url": "https://questionsmedicales.fr/mesh/D000090682#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Neuro-oncological ventral antigen",
"description": "Quels traitements sont disponibles pour les tumeurs associées ?\nL'antigène influence-t-il le choix du traitement ?\nY a-t-il des traitements ciblés pour cet antigène ?\nComment évaluer l'efficacité du traitement ?\nQuels effets secondaires peuvent survenir ?",
"url": "https://questionsmedicales.fr/mesh/D000090682#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Neuro-oncological ventral antigen",
"description": "Quelles complications peuvent survenir avec ces tumeurs ?\nLes complications sont-elles liées au traitement ?\nComment gérer les complications neurologiques ?\nLes complications peuvent-elles affecter la qualité de vie ?\nY a-t-il des complications à long terme ?",
"url": "https://questionsmedicales.fr/mesh/D000090682#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Neuro-oncological ventral antigen",
"description": "Quels sont les principaux facteurs de risque ?\nL'âge influence-t-il le risque de développer ces tumeurs ?\nLes radiations sont-elles un facteur de risque ?\nLes maladies génétiques augmentent-elles le risque ?\nLe sexe influence-t-il le risque de tumeurs cérébrales ?",
"url": "https://questionsmedicales.fr/mesh/D000090682#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment détecte-t-on l'antigène ventral neuro-oncologique ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il est détecté par des tests sanguins et des biopsies tumorales."
}
},
{
"@type": "Question",
"name": "Quels examens sont utilisés pour le diagnostic ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'IRM et le scanner sont couramment utilisés pour visualiser les tumeurs."
}
},
{
"@type": "Question",
"name": "L'antigène est-il spécifique à un type de cancer ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il est principalement associé aux gliomes et aux méningiomes."
}
},
{
"@type": "Question",
"name": "Peut-on utiliser l'antigène pour le suivi des traitements ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les niveaux de l'antigène peuvent indiquer la réponse au traitement."
}
},
{
"@type": "Question",
"name": "Quels marqueurs sont associés à l'antigène ventral ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "D'autres marqueurs comme le GFAP peuvent être utilisés en complément."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont liés aux tumeurs produisant cet antigène ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des maux de tête, des troubles neurologiques et des convulsions."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon le type de tumeur ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes peuvent varier selon la localisation et le type de tumeur."
}
},
{
"@type": "Question",
"name": "L'antigène provoque-t-il des symptômes spécifiques ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, l'antigène lui-même ne provoque pas de symptômes, mais indique une maladie."
}
},
{
"@type": "Question",
"name": "Comment les symptômes évoluent-ils avec le temps ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils peuvent s'aggraver progressivement en fonction de la croissance tumorale."
}
},
{
"@type": "Question",
"name": "Les symptômes peuvent-ils être confondus avec d'autres maladies ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent être similaires à ceux d'autres affections neurologiques."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les tumeurs associées à cet antigène ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de méthode de prévention spécifique pour ces tumeurs."
}
},
{
"@type": "Question",
"name": "Quels facteurs de risque sont connus ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent des antécédents familiaux et des expositions environnementales."
}
},
{
"@type": "Question",
"name": "L'alimentation joue-t-elle un rôle dans la prévention ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée peut contribuer à la santé générale, mais pas spécifiquement."
}
},
{
"@type": "Question",
"name": "Le tabagisme est-il un facteur de risque ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le tabagisme est un facteur de risque pour plusieurs cancers, mais pas spécifiquement pour les tumeurs cérébrales."
}
},
{
"@type": "Question",
"name": "Des examens réguliers peuvent-ils aider ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des examens réguliers peuvent aider à détecter des anomalies, mais pas à prévenir."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles pour les tumeurs associées ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent la chirurgie, la radiothérapie et la chimiothérapie."
}
},
{
"@type": "Question",
"name": "L'antigène influence-t-il le choix du traitement ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la présence de l'antigène peut guider les décisions thérapeutiques."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements ciblés pour cet antigène ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des thérapies ciblées sont en développement, mais pas encore largement disponibles."
}
},
{
"@type": "Question",
"name": "Comment évaluer l'efficacité du traitement ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'efficacité est évaluée par des examens d'imagerie et des tests sanguins réguliers."
}
},
{
"@type": "Question",
"name": "Quels effets secondaires peuvent survenir ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires incluent fatigue, nausées et troubles neurologiques."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec ces tumeurs ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des déficits neurologiques, des infections et des récidives."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles liées au traitement ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains traitements peuvent entraîner des complications supplémentaires."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications neurologiques ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion inclut la rééducation et des traitements symptomatiques."
}
},
{
"@type": "Question",
"name": "Les complications peuvent-elles affecter la qualité de vie ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles peuvent significativement impacter la qualité de vie des patients."
}
},
{
"@type": "Question",
"name": "Y a-t-il des complications à long terme ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications à long terme peuvent inclure des troubles cognitifs et des séquelles physiques."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antécédents familiaux et certaines expositions environnementales sont des facteurs clés."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque de développer ces tumeurs ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque augmente avec l'âge, surtout après 50 ans."
}
},
{
"@type": "Question",
"name": "Les radiations sont-elles un facteur de risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exposition aux radiations ionisantes est un facteur de risque connu."
}
},
{
"@type": "Question",
"name": "Les maladies génétiques augmentent-elles le risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines maladies génétiques, comme la neurofibromatose, augmentent le risque."
}
},
{
"@type": "Question",
"name": "Le sexe influence-t-il le risque de tumeurs cérébrales ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines études montrent que le sexe peut influencer le risque, mais les résultats varient."
}
}
]
}
]
}
Department of Neurology (RVL), Northwestern University, Chicago, IL; The Lou & Jean Malnati Brain Tumor Institute of the Lurie Comprehensive Cancer Center (RVL), Chicago, IL; Departments of Neurology and Neurological Surgery (JWT), University of California-San Francisco; Department of Neurology (SCK), New York University, New York; Brain and Spine Tumor Center at the Perlmutter Cancer Center (SCK), New York, NY; and Department of Neurology (NAM), University of Rochester, NY.
Publications dans "Neuro-oncological ventral antigen" :
Institute of Neuroscience and Medicine (INM-3, INM-4), Research Center Juelich (FZJ), Juelich, Germany; Department of Neurology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany; Brain Tumour Group, European Organization for Research and Treatment of Cancer, Brussels, Belgium; Center for Integrated Oncology, Universities of Aachen, Bonn, Cologne, and Duesseldorf, Cologne, Germany.
Publications dans "Neuro-oncological ventral antigen" :
Department of Pediatrics, Division of Pediatric Neurology and Developmental Neurosciences, Texas Children's Hospital, Baylor College of Medicine, 6701 Fannin Street, Suite 1250, Houston, TX 77030, USA. Electronic address: malbari@bcm.edu.
Publications dans "Neuro-oncological ventral antigen" :
Weill Cornell Brain Tumor Center, Department of Neurology, Weill Cornell Medicine/New York-Presbyterian Hospital, New York, New York, USA. Electronic address: ram9116@med.cornell.edu.
Publications dans "Neuro-oncological ventral antigen" :
Institute of Neuroscience and Medicine (INM-3, INM-4), Research Center Juelich (FZJ), Juelich, Germany; Department of Stereotactic and Functional Neurosurgery, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany; Brain Tumour Group, European Organization for Research and Treatment of Cancer, Brussels, Belgium. Electronic address: p.lohmann@fz-juelich.de.
Publications dans "Neuro-oncological ventral antigen" :
Health disparities are preventable differences in the diagnosis, treatment, and outcomes of many diseases, including central nervous system (CNS) tumors. This review will summarize and compile the exi...
Patients from historically marginalized groups are more likely to receive inadequate treatment, develop complications, and experience a shorter life expectancy. Financial toxicity can be particularly ...
Technical advances and the increasing role of interdisciplinary decision-making may warrant formal definitions of expertise in surgical neuro-oncology....
The EANS Neuro-oncology Section felt that a survey detailing the European neurosurgical perspective on the concept of expertise in surgical neuro-oncology might be helpful....
The EANS Neuro-oncology Section panel developed an online survey asking questions regarding criteria for expertise in neuro-oncological surgery and sent it to all individual EANS members....
Our questionnaire was completed by 251 respondents (consultants: 80.1%) from 42 countries. 67.7% would accept a lifetime caseload of >200 cases and 86.7% an annual caseload of >50 as evidence of neuro...
Opinions among neurosurgeons regarding the characteristics and features of expertise in neuro-oncology vary surprisingly little. Large majorities favoring certain thresholds and qualitative criteria s...
Historically, the practice of neurology as an independent subspecialty from internal medicine began in Europe and the United States in the 1930s. The American Academy of Neurology (AAN) was founded 75...
Artificial intelligence (AI) describes the application of computer algorithms to the solution of problems that have traditionally required human intelligence. Although formal work in AI has been slowl...
Although most primary central and peripheral nervous system (NS) tumors occur sporadically, there are a subset that may arise in the context of a cancer predisposition syndrome. These syndromes occur ...
Primary malignant and non-malignant brain and other central nervous system (CNS) tumors, while relatively rare, are a disproportionate source of morbidity and mortality. Here we provide a brief overvi...
An important factor contributing to the low rate of success in identifying effective therapies for brain tumor patients is the slow, inefficient, and expensive process of drug development, as well as ...
Surgical 'window-of-opportunity' trials that evaluate tumor drug concentrations and pharmacodynamic effects provide invaluable early data early guiding the development of novel therapies. Basket and b...
These novel designs will hopefully reduce the inefficiencies of developing novel therapies in neuro-oncology and facilitate the identification of more effective therapies for brain tumor patients....
While the benefits of palliative care for patients with cancer are well established, palliative care in neuro-oncology is still in its early stages. However, in recent years, there has been increasing...
There is a growing body of literature demonstrating the high symptom burden and significant supportive care and information needs of these patients and their caregivers. In the area of caregiver needs...
The nervous system is an important component of the tumor microenvironment (TME), driving tumorigenesis and tumor progression. Neuronal cues (e.g., neurotransmitters and neuropeptides) in the TME caus...
Burnout is a syndrome characterized by emotional exhaustion, depersonalization, and a reduced sense of accomplishment, which commonly arises from chronic workplace stress in the medical field. Given t...
We distributed an anonymous online survey to SNO members in 2019. Only those meeting the definition of a YI were asked to complete the survey. The survey consisted of questions about personal and prof...
Data were analyzed for 173 participants who self-identified as YI. Measures of burnout showed that YI members scored higher on emotional exhaustion and depersonalization compared to normative populati...
Similar to results from a previous survey completed by general SNO membership, the prevalence of burnout among neuro-oncology clinical and research YI is high, and is mainly characterized by overexten...